The thought of starting a family at a fertility clinic shouldn't be a dream, it should be a tangeable reality.
Goodbye 30% fertility plateau.
Incintas is about to replace you with much better odds to achieve pregnancy in assisted reproduction.
IVF / IUI / Artificial Insemination / Timed Intercourse
INCINTAS THERAPEUTICS, INC.
Driving cutting edge technology in assisted reproduction.
Incintas improves receptivity by using targeted extended release hormonal therapeutics administered directly where implantation occurs; inside the uterus.....not the bloodstream.
What is Known:
It is imperative for the "Window of Implantation" to be open in order for pregnancy to be achieved both in healthy pregnancy and in Assisted Reproduction Technologies (ART) that include; IVF, IUI, artificial insemination and timed intercourse treatments. When this window is closed, pregnancy is impossible because the embryo cannot implant into the uterine lining.
Did you know?
The current Implantation Window in ART
is only "open" for 24 hours on average, compared to 6 days in healthy pregnancy. This is the rate limiting factor in achieving pregnancy since the very first IVF baby was born in 1978.
THE SCIENCE BEHIND THE INNOVATION
When women undergo fertitlity treatment, it is necessary to administer progesterone (the pregnancy hormone) to make the uterine lining receptive. They are given what is called "luteal phase support" which is progesteroe that is either administered perivaginally, via IM injection, orally, rectally or via subcutaneous injection. These administrations allow progesterone to travel through the woman's bloodstream to achieve two important goals; 1. establish a receptive uterine lining so that an embryo can implant and acheive pregnancy and, 2. maintain the pregnancy by preventing menses and loss of the pregnancy.
The problem with these conventional adminitrations is that they do the second task really well but fail miserably at the first one (establishing uterine receptivity). When progesterone is allowed to travel through the bloodstream it does not provide the proper concentration range within the uterine lining for more than about 24 hrs. This is a big problem because it restricts embryonic implantation for most embryos, which is the biggest hurdle and rate limiting factor in achiving pregnancy since the 1970s.
Incintas Therapeutics has separated these administrations into two distinct aspects that involves a novel targeted intratuerine/peri-uterine administration, solely intended to prolong endometrial receptivity and allow an embryo more time to implant and achieve pregnancy. After pregnancy is achieved, conventional luteal phase support is administered using any of the aforementioned routes of administration. These administrations do a great job at sustaining the pregnancy until the placenta synthesizes progesterone naturally around week 10-12.
This novel refined protocol implements two distinct routes of administration using time-release capabilites that are in current development and patent protected by Incintas Therapeutics, Inc.
Unlike all other IVF products on the market,
Incintas' technology doesn't monitor embryonic receptivity,
it precisely modulates it by administering progesterone directly where implantation occurs.
About Us
WHAT WE DO
"We intend to move the needle pretty far in assisted reproduction by focusing upon failed implantation."
Incintas Therapeutics is comprised of an accomplished team of scientists, physicians, geneticists and business professionals who are focused upon improving pregnancy outcome in reproductive medicine.
Our sole purpose is to resolve the problem of failed embryonic implantation (the main hurdle in achieving pregnancy in IVF) to ultimately encourage Single Embryo Transfer (SET) which is more likely to result in a healthy singleton pregnancy for the infertile couple.
DISCOVERY
Endometrial Progesterone Concentration associated with 73-81% implantation and live birth rate.
Reproductive scientists have been relying upon blood progesterone concentrations to identify when the uterus is receptive to a transfered embryo. This improper practice has misguided the entire field of assisted reproduction for decades.*
*Measuring serum progesterone is not a reliable means of determining uterine receptivity,
(E. Labarta, 2021 and B. Lawrenz, 2024)
Mitchell V. Pizolato,
Nov. 23 -Nov. 29, 2000.
Multiple IVF Birth
Lance D. Pizolato
Nov. 23 - Dec. 1, 2000
Multiple IVF Birth
Rest in Peace, my dear sons.
